RE: RNS15 Mar 2021 08:05
"Starbright-
The Company notes that under UK Government Public Sector contract disclosure rules this number necessarily represents a maximum of the potential value of the contract and care should be taken not to use this number as an estimate or forecast of the actual likely value of purchase orders to be received by the Company for the production of COVID-19 lateral flow antigen tests.
If you then go back to the master contract anouncement it has multiple companies invloved, hence above careful wording by CK. Likewise due to uncertainty of the govt test selection, CK previously advised that we will prodcue any tests the govt selects."
Sorry - you're misunderstanding the position and incorrectly conflating irrelevant items.
The Framework (the Dynamic Purchasing System) has a number of suppliers on it. The Framework is not a supply Contract.
What was published yesterday was a Contract Award Notice for a supply Contract under the Framework.
The £374m supply Contract clearly states that it relates solely to Omega Diagnostics. The Contract does not relate to any other supplier.
As I pointed out earlier, and Omega makes clear in the RNS, the £374m is the maximum potential value of the Contract to Omega (and just Omega) over the lifetime of the Contract. However, this is not a Contract for a fixed volume, so the actual value could be less (a minimum of £50m).
Those are the facts.